Ipilimumab vs Nitroglycerin
Ipilimumab vs Nitroglycerin: Overview
This comparison examines the pharmacological differences between Ipilimumab and Nitroglycerin.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Nitroglycerin: Nitric oxide donor causing venous and arterial vasodilation.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days; Nitroglycerin β 1-4 minutes.
Chemical Properties
Molecular Formula: Nitroglycerin β C3H5N3O9.
Molecular Weight: Nitroglycerin β 227.0870 g/mol.
Type: Ipilimumab β Antibody; Nitroglycerin β Small molecule.